{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:41:40Z","timestamp":1792554100061,"version":"4.5.0"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105274","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:13:45Z","timestamp":1604715225000},"page":"105274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":243,"special_numbering":"C","title":["HDAC6 as privileged target in drug discovery: A perspective"],"prefix":"10.1016","volume":"163","author":[{"given":"Sravani","family":"Pulya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sk. Abdul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaram","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105274_bib0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00439-013-1271-x","article-title":"Genetic syndromes caused by mutations in epigenetic genes","volume":"132","author":"Berdasco","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.phrs.2020.105274_bib0010","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1755-8794-8-S1-S5","article-title":"The role of epigenetics in personalized medicine: challenges and opportunities","volume":"8","author":"Rasool","year":"2015","journal-title":"BMC Medical Genomics."},{"key":"10.1016\/j.phrs.2020.105274_bib0015","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science."},{"key":"10.1016\/j.phrs.2020.105274_bib0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 \u00c5 resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105274_bib0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.184.4139.868","article-title":"Chromatin Structure: A Repeating Unit of Histones and DNA","volume":"184","author":"Kornberg","year":"1974","journal-title":"Science."},{"key":"10.1016\/j.phrs.2020.105274_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105274_bib0035","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/anie.200461346","article-title":"Epigenetics\u2014An Epicenter of Gene Regulation: Histones and Histone-Modifying Enzymes","volume":"44","author":"Biel","year":"2005","journal-title":"Angewandte Chemie International Edition."},{"key":"10.1016\/j.phrs.2020.105274_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0959-437X(00)00173-8","article-title":"Histone acetyltransferases: function, structure, and catalysis","volume":"11","author":"Marmorstein","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.phrs.2020.105274_bib0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.2000.5080","article-title":"The human histone deacetylase family","volume":"262","author":"Gray","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Experimental & Molecular Medicine."},{"key":"10.1016\/j.phrs.2020.105274_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review","volume":"192","author":"Sarkar","year":"2020","journal-title":"European Journal of Medicinal Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene."},{"key":"10.1016\/j.phrs.2020.105274_bib0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15216540500090629","article-title":"Transcriptional Regulation by the Acetylation of Nonhistone Proteins in Humans - A New Target for Therapeutics","volume":"57","author":"Das","year":"2005","journal-title":"IUBMB Life."},{"key":"10.1016\/j.phrs.2020.105274_bib0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J."},{"key":"10.1016\/j.phrs.2020.105274_bib0075","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","article-title":"Recent advances in the discovery of potent and selective HDAC6 inhibitors","volume":"143","author":"Wang","year":"2018","journal-title":"European Journal of Medicinal Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105274_bib0085","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1021\/jm0505011","article-title":"Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases","volume":"48","author":"Wang","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ejmech.2018.08.081","article-title":"HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches","volume":"157","author":"Adhikari","year":"2018","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0095","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","article-title":"Three proteins define a class of human histone deacetylases related to yeast Hda1p","volume":"96","author":"Grozinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2020.105274_bib0100","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"The FEBS Journal."},{"key":"10.1016\/j.phrs.2020.105274_bib0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105274_bib0110","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.9b00560","article-title":"Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor","author":"Shen","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Sim\u00f5es-Pires","year":"2013","journal-title":"Molecular Neurodegeneration."},{"key":"10.1016\/j.phrs.2020.105274_bib0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"Journal of Hematology & Oncology."},{"key":"10.1016\/j.phrs.2020.105274_bib0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/emmm.201201923","article-title":"Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer\u2019s disease","volume":"5","author":"Govindarajan","year":"2013","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.phrs.2020.105274_bib0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/acs.jmedchem.9b01540","article-title":"Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6","volume":"63","author":"Osko","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105046","article-title":"Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity","volume":"138","author":"Trivedi","year":"2019","journal-title":"European Journal of Pharmaceutical Sciences."},{"key":"10.1016\/j.phrs.2020.105274_bib0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejps.2018.08.030","article-title":"Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects","volume":"124","author":"Trivedi","year":"2018","journal-title":"European Journal of Pharmaceutical Sciences."},{"key":"10.1016\/j.phrs.2020.105274_bib0150","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1080\/07391102.2018.1477625","article-title":"Designing potential HDAC3 inhibitors to improve memory and learning","volume":"37","author":"Amin","year":"2019","journal-title":"Journal of Biomolecular Structure and Dynamics."},{"key":"10.1016\/j.phrs.2020.105274_bib0155","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bmcl.2016.01.022","article-title":"Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation","volume":"26","author":"Ghosh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib0160","doi-asserted-by":"crossref","DOI":"10.1039\/D0NJ01274B","article-title":"Design, synthesis, and biological evaluation of novel nicotinamide derivatives as potential histone deacetylase-3 inhibitors","author":"Hamoud","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet."},{"key":"10.1016\/j.phrs.2020.105274_bib0170","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science."},{"key":"10.1016\/j.phrs.2020.105274_bib0175","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1073\/pnas.93.23.12845","article-title":"Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3","volume":"93","author":"Yang","year":"1996","journal-title":"PNAS."},{"key":"10.1016\/j.phrs.2020.105274_bib0180","doi-asserted-by":"crossref","first-page":"28001","DOI":"10.1074\/jbc.272.44.28001","article-title":"Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family","volume":"272","author":"Yang","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0185","doi-asserted-by":"crossref","first-page":"15254","DOI":"10.1074\/jbc.M908988199","article-title":"Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor","volume":"275","author":"Hu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1101\/gad.14.1.55","article-title":"Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression","volume":"14","author":"Kao","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2020.105274_bib0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1074\/jbc.M108931200","article-title":"Isolation and characterization of mammalian HDAC10, a novel histone deacetylase","volume":"277","author":"Kao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.97.3.1056","article-title":"Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5","volume":"97","author":"Zhou","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2020.105274_bib0205","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of Histone Acetylation: The Histone Deacetylase Enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0210","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbrc.2005.12.144","article-title":"Characterization of the Two Catalytic Domains in Histone Deacetylase 6","volume":"341","author":"Zou","year":"2006","journal-title":"Biochemical and Biophysical Research Communications."},{"key":"10.1016\/j.phrs.2020.105274_bib0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics."},{"key":"10.1016\/j.phrs.2020.105274_bib0225","doi-asserted-by":"crossref","first-page":"48246","DOI":"10.1074\/jbc.M408583200","article-title":"Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention","volume":"279","author":"Bertos","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0230","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/sj.onc.1210614","article-title":"HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination","volume":"26","author":"Boyault","year":"2007","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.105274_bib0235","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1242\/jcs.03431","article-title":"HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions","volume":"120","author":"Tran","year":"2007","journal-title":"Journal of Cell Science."},{"key":"10.1016\/j.phrs.2020.105274_bib0240","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"PNAS."},{"key":"10.1016\/j.phrs.2020.105274_bib0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2020.105274_bib0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbrc.2009.03.147","article-title":"Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity","volume":"383","author":"Han","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.105274_bib0255","doi-asserted-by":"crossref","first-page":"13425","DOI":"10.1073\/pnas.172511699","article-title":"Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes","volume":"99","author":"Hook","year":"2002","journal-title":"PNAS."},{"key":"10.1016\/j.phrs.2020.105274_bib0260","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/emboj.2011.466","article-title":"A novel GRK2\/HDAC6 interaction modulates cell spreading and motility","volume":"31","author":"Lafarga","year":"2012","journal-title":"The EMBO Journal."},{"key":"10.1016\/j.phrs.2020.105274_bib0265","doi-asserted-by":"crossref","first-page":"33156","DOI":"10.1074\/jbc.M113.472506","article-title":"Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration","volume":"288","author":"Williams","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123191","article-title":"aPKC Phosphorylation of HDAC6 Results in Increased Deacetylation Activity","volume":"10","author":"Du","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.phrs.2020.105274_bib0275","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.cell.2007.04.035","article-title":"HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary Cilium","volume":"129","author":"Pugacheva","year":"2007","journal-title":"Cell."},{"key":"10.1016\/j.phrs.2020.105274_bib0280","article-title":"HDAC6 Regulates Mitochondrial Transport in Hippocampal Neurons","volume":"5","author":"Chen","year":"2010","journal-title":"PLoS One."},{"key":"10.1016\/j.phrs.2020.105274_bib0285","article-title":"Regulation of Epidermal Growth Factor Receptor Trafficking by Lysine Deacetylase HDAC6","volume":"2","author":"Deribe","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2020.105274_bib0290","unstructured":"https:\/\/www.rcsb.org\/, (n.d.)."},{"key":"10.1016\/j.phrs.2020.105274_bib0295","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nchembio.2158","article-title":"HDAC6 finally crystal clear","volume":"12","author":"Liu","year":"2016","journal-title":"Nature Chemical Biology."},{"key":"10.1016\/j.phrs.2020.105274_bib0300","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/cmdc.202000149","article-title":"Design and Synthesis of Dihydroxamic Acids as HDAC6\/8\/10 Inhibitors","volume":"15","author":"Morgen","year":"2020","journal-title":"ChemMedChem."},{"key":"10.1016\/j.phrs.2020.105274_bib0305","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/acs.biochem.9b00934","article-title":"Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6","volume":"58","author":"Osko","year":"2019","journal-title":"Biochemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0310","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1021\/acs.jmedchem.9b00946","article-title":"Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models","volume":"62","author":"Shen","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0315","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/acsmedchemlett.8b00487","article-title":"Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor","volume":"9","author":"Porter","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib0320","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/acs.jmedchem.8b01487","article-title":"Discovery of the First-in-Class Dual Histone Deacetylase\u2013Proteasome Inhibitor","volume":"61","author":"Bhatia","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0325","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0330","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","article-title":"Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors","volume":"62","author":"V\u00f6gerl","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0335","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/acs.orglett.8b01118","article-title":"Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors","volume":"20","author":"Mackwitz","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib0340","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/acs.biochem.8b00367","article-title":"Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6","volume":"57","author":"Porter","year":"2018","journal-title":"Biochemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0345","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","article-title":"Identification and Structure\u2013Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors","volume":"61","author":"Ferreira de Freitas","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0350","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"PNAS."},{"key":"10.1016\/j.phrs.2020.105274_bib0355","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1021\/acs.jmedchem.7b00933","article-title":"Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin","volume":"60","author":"Harding","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0360","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nature Chemical Biology."},{"key":"10.1016\/j.phrs.2020.105274_bib0365","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0370","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1074\/jbc.M111.273730","article-title":"Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini","volume":"287","author":"Ouyang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127023","article-title":"Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6","volume":"30","author":"Osko","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters."},{"key":"10.1016\/j.phrs.2020.105274_bib0380","series-title":"Biovia, USA., n.d","author":"Biovia","year":"2016"},{"key":"10.1016\/j.phrs.2020.105274_bib0385","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","article-title":"HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2020.105274_bib0390","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell."},{"key":"10.1016\/j.phrs.2020.105274_bib0395","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2020.105274_bib0400","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4161\/cc.7.1.5186","article-title":"HDAC6 a new cellular stress surveillance factor","volume":"7","author":"Matthias","year":"2008","journal-title":"Cell Cycle."},{"key":"10.1016\/j.phrs.2020.105274_bib0405","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2020.105274_bib0410","first-page":"1","article-title":"Acetylation modification regulates GRP78 secretion in colon cancer cells","volume":"6","author":"Li","year":"2016","journal-title":"Scientific Reports."},{"key":"10.1016\/j.phrs.2020.105274_bib0415","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1083\/jcb.201702187","article-title":"Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition","volume":"218","author":"Kalinski","year":"2019","journal-title":"J Cell Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0420","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1083\/jcb.201904016","article-title":"HDAC6 and Miro1: Another interaction causing trouble in neurons","volume":"218","author":"Van Den Bosch","year":"2019","journal-title":"J Cell Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0425","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1073\/pnas.0803749105","article-title":"HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation","volume":"105","author":"Parmigiani","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.phrs.2020.105274_bib0430","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/cdd.2012.8","article-title":"Identification of an acetylation-dependant Ku70\/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis","volume":"19","author":"Kerr","year":"2012","journal-title":"Cell Death & Differentiation."},{"key":"10.1016\/j.phrs.2020.105274_bib0435","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M117.795955","article-title":"Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity","volume":"293","author":"Wu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0440","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells","volume":"35","author":"Kr\u00e4mer","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2020.105274_bib0445","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0450","series-title":"HDAC6 – An Emerging Target against Chronic Myeloid Leukemia?","author":"Losson","year":"2020"},{"key":"10.1016\/j.phrs.2020.105274_bib0455","doi-asserted-by":"crossref","first-page":"10885","DOI":"10.1074\/jbc.M111.308791","article-title":"Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer","volume":"287","author":"Riolo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0460","doi-asserted-by":"crossref","first-page":"7982","DOI":"10.1128\/MCB.22.22.7982-7992.2002","article-title":"Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1\/WAF1 Promoter","volume":"22","author":"Westendorf","year":"2002","journal-title":"Molecular and Cellular Biology."},{"key":"10.1016\/j.phrs.2020.105274_bib0465","doi-asserted-by":"crossref","first-page":"30264","DOI":"10.1074\/jbc.M109.045526","article-title":"Function of Histone Deacetylase 6 as a Cofactor of Nuclear Receptor Coregulator LCoR","volume":"284","author":"Palijan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0470","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00156.2002","article-title":"NF-kappaB inhibits transcription of the H(+)-K(+)-ATPase alpha(2)-subunit gene: role of histone deacetylases","volume":"283","author":"Zhang","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.phrs.2020.105274_bib0475","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00052-19","article-title":"The Acetylation of Lysine-376 of G3BP1 Regulates RNA Binding and Stress Granule Dynamics","volume":"39","author":"Gal","year":"2019","journal-title":"Molecular and Cellular Biology."},{"key":"10.1016\/j.phrs.2020.105274_bib0480","first-page":"1","article-title":"HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN\/AKT\/mTOR pathway","volume":"10","author":"Zheng","year":"2020","journal-title":"Scientific Reports."},{"key":"10.1016\/j.phrs.2020.105274_bib0485","first-page":"819","article-title":"HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin","volume":"27","author":"Zuo","year":"2012","journal-title":"Oncology Reports."},{"key":"10.1016\/j.phrs.2020.105274_bib0490","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.febslet.2013.02.001","article-title":"HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity","volume":"587","author":"Ding","year":"2013","journal-title":"FEBS Letters."},{"key":"10.1016\/j.phrs.2020.105274_bib0495","first-page":"7082","article-title":"Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt\/\u03b2\u2011catenin signaling pathway in hepatocellular carcinoma","volume":"16","author":"Yin","year":"2018","journal-title":"Oncology Letters."},{"key":"10.1016\/j.phrs.2020.105274_bib0500","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","article-title":"Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation","volume":"9","author":"Woan","year":"2015","journal-title":"Molecular Oncology."},{"key":"10.1016\/j.phrs.2020.105274_bib0505","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.bbrc.2017.12.145","article-title":"HDAC6 interacts with PTPN1 to enhance melanoma cells progression","volume":"495","author":"Liu","year":"2018","journal-title":"Biochemical and Biophysical Research Communications."},{"key":"10.1016\/j.phrs.2020.105274_bib0510","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","article-title":"Essential role of HDAC6 in the regulation of PD-L1 in melanoma","volume":"10","author":"Lienlaf","year":"2016","journal-title":"Molecular Oncology."},{"key":"10.1016\/j.phrs.2020.105274_bib0515","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2008.06.092","article-title":"Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells","volume":"374","author":"Kamemura","year":"2008","journal-title":"Biochemical and Biophysical Research Communications."},{"key":"10.1016\/j.phrs.2020.105274_bib0520","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-016-0765-5","article-title":"HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells","volume":"33","author":"Wang","year":"2016","journal-title":"Med Oncol."},{"key":"10.1016\/j.phrs.2020.105274_bib0525","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.98","article-title":"Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells","volume":"48","author":"Lim","year":"2016","journal-title":"Experimental & Molecular Medicine."},{"key":"10.1016\/j.phrs.2020.105274_bib0530","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4749","article-title":"Nuclear HDAC6 inhibits invasion by suppressing NF-\u03baB\/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.105274_bib0535","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1038\/sj.onc.1208646","article-title":"Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer","volume":"24","author":"Saji","year":"2005","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.105274_bib0540","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/onc.2015.214","article-title":"Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer","volume":"35","author":"Chang","year":"2016","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.105274_bib0545","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbamcr.2019.03.003","article-title":"Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo","volume":"1866","author":"Hsieh","year":"2019","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.phrs.2020.105274_bib0550","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0658-0","article-title":"HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers","volume":"17","author":"Putcha","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0555","first-page":"117","article-title":"Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma","volume":"29","author":"Sakuma","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2020.105274_bib0560","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2012.02.026","article-title":"HDAC6 as a target for antileukemic drugs in acute myeloid leukemia","volume":"36","author":"Hackanson","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0565","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1182\/bloodadvances.2018020065","article-title":"Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia","volume":"2","author":"Maharaj","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2020.105274_bib0570","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijms19082337","article-title":"The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease","volume":"19","author":"Cosenza","year":"2018","journal-title":"International Journal of Molecular Sciences."},{"key":"10.1016\/j.phrs.2020.105274_bib0575","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05853","article-title":"HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS","volume":"447","author":"Pandey","year":"2007","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105274_bib0580","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.105274_bib0585","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-2012-120727","article-title":"The role of HDAC6 in Alzheimer\u2019s disease","volume":"33","author":"Zhang","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2020.105274_bib0590","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/alzrt241","article-title":"Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition","volume":"6","author":"Selenica","year":"2014","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.phrs.2020.105274_bib0595","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/j.1471-4159.2008.05564.x","article-title":"Histone deacetylase 6 interacts with the microtubule-associated protein tau","volume":"106","author":"Ding","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2020.105274_bib0600","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00537","article-title":"Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation","volume":"11","author":"Shukla","year":"2020","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.phrs.2020.105274_bib0605","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective vulnerability in \u03b1-synucleinopathies","volume":"138","author":"Alegre-Abarrategui","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2020.105274_bib0610","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.neurobiolaging.2014.04.029","article-title":"Histone deacetylase 6 regulates cytotoxic \u03b1-synuclein accumulation through induction of the heat shock response","volume":"35","author":"Du","year":"2014","journal-title":"Neurobiology of Aging."},{"key":"10.1016\/j.phrs.2020.105274_bib0615","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/auto.5190","article-title":"Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome","volume":"4","author":"Ding","year":"2008","journal-title":"Autophagy."},{"key":"10.1016\/j.phrs.2020.105274_bib0620","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1083\/jcb.200611128","article-title":"Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6","volume":"178","author":"Olzmann","year":"2007","journal-title":"J Cell Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0625","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1083\/jcb.201001039","article-title":"Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy","volume":"189","author":"Lee","year":"2010","journal-title":"J Cell Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62678-5","article-title":"Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity","volume":"10","author":"Francelle","year":"2020","journal-title":"Scientific Reports."},{"key":"10.1016\/j.phrs.2020.105274_bib0635","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M508786200","article-title":"HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin","volume":"280","author":"Iwata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0640","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington\u2019s disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2020.105274_bib0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020696","article-title":"Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6\/2 Mouse Model of Huntington\u2019s Disease","volume":"6","author":"Bobrowska","year":"2011","journal-title":"PLoS One."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2020.105274_bib0650","article-title":"Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome","volume":"23","author":"Van den Veyver","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.phrs.2020.105274_bib0655","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00109-014-1202-x","article-title":"MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors","volume":"93","author":"Gold","year":"2015","journal-title":"J Mol Med."},{"key":"10.1016\/j.phrs.2020.105274_bib0660","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2020.105274_bib0665","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00068","article-title":"A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome","volume":"8","author":"Xu","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.phrs.2020.105274_bib0670","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nm.2396","article-title":"HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1\u2013induced Charcot-Marie-Tooth disease","volume":"17","author":"d\u2019Ydewalle","year":"2011","journal-title":"Nature Medicine."},{"key":"10.1016\/j.phrs.2020.105274_bib0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03461-z","article-title":"Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy","volume":"9","author":"Mo","year":"2018","journal-title":"Nature Communications."},{"key":"10.1016\/j.phrs.2020.105274_bib0680","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/brain\/awx375","article-title":"HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease","volume":"141","author":"Benoy","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.phrs.2020.105274_bib0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146692","article-title":"HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT","volume":"1733","author":"Rossaert","year":"2020","journal-title":"Brain Research."},{"key":"10.1016\/j.phrs.2020.105274_bib0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113281","article-title":"HDAC6 inhibition promotes \u03b1-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice","volume":"328","author":"Picci","year":"2020","journal-title":"Experimental Neurology."},{"key":"10.1016\/j.phrs.2020.105274_bib0695","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.phrs.2020.105274_bib0700","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0705","first-page":"84","article-title":"Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.phrs.2020.105274_bib0710","first-page":"22","article-title":"Romidepsin for the Treatment of Peripheral T-Cell Lymphoma","volume":"6","author":"Barbarotta","year":"2015","journal-title":"J Adv Pract Oncol."},{"key":"10.1016\/j.phrs.2020.105274_bib0715","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0720","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","article-title":"SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer","volume":"9","author":"Novotny-Diermayr","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.105274_bib0725","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1074-5521(03)00095-4","article-title":"Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays","volume":"10","author":"Haggarty","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2020.105274_bib0730","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1021\/jm7015254","article-title":"Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors","volume":"51","author":"Estiu","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0735","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnins.2011.00103","article-title":"Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms","volume":"5","author":"Roberds","year":"2011","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2020.105274_bib0740","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.intimp.2013.03.016","article-title":"Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects","volume":"16","author":"Vishwakarma","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2020.105274_bib0745","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1134\/S0006297914070050","article-title":"Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes","volume":"79","author":"Kozlov","year":"2014","journal-title":"Biochemistry Moscow."},{"key":"10.1016\/j.phrs.2020.105274_bib0750","article-title":"Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of \u03b1-tubulin acetylation and FGF-21 up-regulation","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.phrs.2020.105274_bib0755","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vph.2015.04.006","article-title":"Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes","volume":"72","author":"Choi","year":"2015","journal-title":"Vascular Pharmacology."},{"key":"10.1016\/j.phrs.2020.105274_bib0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186615","article-title":"Tubastatin ameliorates pulmonary fibrosis by targeting the TGF\u03b2-PI3K-Akt pathway","volume":"12","author":"Saito","year":"2017","journal-title":"PLOS ONE."},{"key":"10.1016\/j.phrs.2020.105274_bib0765","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.2147\/IJN.S136142","article-title":"Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer","volume":"12","author":"Yuan","year":"2017","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.phrs.2020.105274_bib0770","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0775","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181916","article-title":"The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci Rep."},{"key":"10.1016\/j.phrs.2020.105274_bib0780","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2020.105274_bib0785","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.13315","article-title":"Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death","volume":"169","author":"Mishima","year":"2015","journal-title":"British Journal of Haematology."},{"key":"10.1016\/j.phrs.2020.105274_bib0790","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.phrs.2020.105274_bib0795","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2020.105274_bib0800","doi-asserted-by":"crossref","unstructured":"M. Cosenza, M. Civallero, L. Marcheselli, S. Sacchi, S. Pozzi, Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine, Apoptosis. 22 (2017) 827\u2013840. https:\/\/doi.org\/10.1007\/s10495-017-1364-4.","DOI":"10.1007\/s10495-017-1364-4"},{"key":"10.1016\/j.phrs.2020.105274_bib0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0788-2","article-title":"Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death & Disease."},{"key":"10.1016\/j.phrs.2020.105274_bib0810","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3040.3040","article-title":"ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD\u00ae) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)","volume":"126","author":"Niesvizky","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2020.105274_bib0815","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.105274_bib0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLoS ONE."},{"key":"10.1016\/j.phrs.2020.105274_bib0825","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3307.3307","article-title":"Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)","volume":"128","author":"Niesvizky","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2020.105274_bib0830","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13311-016-0501-z","article-title":"Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot\u2013Marie\u2013Tooth Disease","volume":"14","author":"Benoy","year":"2017","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.phrs.2020.105274_bib0835","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/npp.2013.207","article-title":"J.H. Van Duzer, S. Jones, O. Berton, Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability","volume":"39","author":"Jochems","year":"2014","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.phrs.2020.105274_bib0840","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fneur.2019.00519","article-title":"The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis","volume":"10","author":"LoPresti","year":"2019","journal-title":"Front Neurol."},{"key":"10.1016\/j.phrs.2020.105274_bib0845","first-page":"e28","article-title":"An HDAC6 inhibitor for treatment of chemotherapy-induced peripheral numbness and pain in a mouse model, Brain, Behavior","volume":"49","author":"Krukowski","year":"2015","journal-title":"and Immunity."},{"key":"10.1016\/j.phrs.2020.105274_bib0850","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40478-018-0604-3","article-title":"Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment","volume":"6","author":"Ma","year":"2018","journal-title":"Acta Neuropathologica Communications."},{"key":"10.1016\/j.phrs.2020.105274_bib0855","doi-asserted-by":"crossref","first-page":"15704","DOI":"10.1073\/pnas.1313893110","article-title":"Development of a histone deacetylase 6 inhibitor and its biological effects","volume":"110","author":"Lee","year":"2013","journal-title":"PNAS."},{"key":"10.1016\/j.phrs.2020.105274_bib0860","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1073\/pnas.1515882112","article-title":"Creation of a histone deacetylase 6 inhibitor and its biological effects","volume":"112","author":"Lee","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.phrs.2020.105274_bib0865","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejmech.2016.03.046","article-title":"Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity","volume":"116","author":"Yoo","year":"2016","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0870","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.bmc.2019.06.036","article-title":"Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors","volume":"27","author":"Nam","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.phrs.2020.105274_bib0875","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1021\/jm5008962","article-title":"Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors","volume":"57","author":"Tang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0880","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1021\/jm502011f","article-title":"Design and Synthesis of Orally Bioavailable Aminopyrrolidinone Histone Deacetylase 6 Inhibitors","volume":"58","author":"Lin","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0885","doi-asserted-by":"crossref","first-page":"9868","DOI":"10.1039\/C5CC03295D","article-title":"Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors","volume":"51","author":"Vreese","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.phrs.2020.105274_bib0890","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1039\/c3cc41422a","article-title":"Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A","volume":"49","author":"Vreese","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.phrs.2020.105274_bib0895","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1039\/C5OB02625C","article-title":"Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors","volume":"14","author":"Vreese","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0900","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/chem.201604167","article-title":"Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold","volume":"23","author":"De Vreese","year":"2017","journal-title":"Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0905","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.5b01493","article-title":"Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors","volume":"59","author":"Senger","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0910","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1039\/C5CC10301K","article-title":"Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors","volume":"52","author":"Diedrich","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.phrs.2020.105274_bib0915","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1021\/acscentsci.7b00274","article-title":"HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination","volume":"3","author":"Strebl","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.phrs.2020.105274_bib0920","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acschemneuro.5b00286","article-title":"Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot\u2013Marie\u2013Tooth Disease","volume":"7","author":"Shen","year":"2016","journal-title":"ACS Chem Neurosci."},{"key":"10.1016\/j.phrs.2020.105274_bib0925","first-page":"905","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo, J. Med","volume":"61","author":"Lee","year":"2018","journal-title":"Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0930","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-018-0688-5","article-title":"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer\u2019s disease model","volume":"9","author":"Fan","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2020.105274_bib0935","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1021\/acs.jmedchem.8b00151","article-title":"5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer\u2019s Disease Phenotypes","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0940","series-title":"Alpha-Amino Acid Derivatives with Antiinflammatory Activity","author":"Pinori","year":"2006"},{"key":"10.1016\/j.phrs.2020.105274_bib0945","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1021\/acs.jmedchem.9b01194","article-title":"Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation","volume":"62","author":"Vergani","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0950","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/acsmedchemlett.9b00084","article-title":"Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib0955","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejmech.2018.12.056","article-title":"A novel class of anthraquinone-based HDAC6 inhibitors","volume":"164","author":"Song","year":"2019","journal-title":"European Journal of Medicinal Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0960","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms20246213","article-title":"Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction","volume":"20","author":"Sharma","year":"2019","journal-title":"International Journal of Molecular Sciences."},{"key":"10.1016\/j.phrs.2020.105274_bib0965","first-page":"6775","article-title":"Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer\u2019s disease, J. Med","volume":"56","author":"Yu","year":"2013","journal-title":"Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0970","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acs.jmedchem.8b01590","article-title":"Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"62","author":"Yu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0975","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bcp.2019.03.023","article-title":"High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma","volume":"163","author":"Liu","year":"2019","journal-title":"Biochemical Pharmacology."},{"key":"10.1016\/j.phrs.2020.105274_bib0980","doi-asserted-by":"crossref","first-page":"111950","DOI":"10.1016\/j.ejmech.2019.111950","article-title":"5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity","volume":"187","author":"Chen","year":"2020","journal-title":"European Journal of Medicinal Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0985","doi-asserted-by":"crossref","first-page":"112086","DOI":"10.1016\/j.ejmech.2020.112086","article-title":"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo","volume":"190","author":"Ojha","year":"2020","journal-title":"European Journal of Medicinal Chemistry."},{"key":"10.1016\/j.phrs.2020.105274_bib0990","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/jm301355j","article-title":"Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif","volume":"56","author":"Wagner","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105274_bib0995","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acsmedchemlett.7b00012","article-title":"Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors","volume":"8","author":"Lv","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105274_bib1000","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","article-title":"Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function","volume":"6","author":"Segretti","year":"2015","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:27:01Z","timestamp":1760912821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820315826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":200,"alternative-id":["S1043661820315826"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105274","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC6 as privileged target in drug discovery: A perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105274"}}